TRDA News and Press, Entrada Therapeutics Inc. From 01/09/23

BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the selection o...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

Entrada Therapeutics ( NASDAQ: TRDA ) on Monday said the U.S. Food and Drug Administration (FDA) had put the company's investigational new drug application (IND) for its muscle wasting therapy on a clinical hold. Shares of the small-cap biopharma slumped 34.6% to $13 after hours. ...

BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced that the Compan...

Entrada Therapeutics ( NASDAQ: TRDA ) added ~13% pre-market Thursday after the biotech announced a four-year global research collaboration with Vertex Pharmaceuticals ( NASDAQ: VRTX ) targeting muscular disorder myotonic dystrophy type 1 (DM1). Per the terms, Vertex ( VR...

- Entrada to receive $224 million upfront payment and $26 million equity investment, as well as potential milestone payments and royalties - - Global collaboration includes ENTR-701, Entrada’s EEV-investigational candidate for the treatment of DM1 - Vertex Pharmaceutica...

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEV TM ) therapeutic...

Entrada Therapeutics press release ( NASDAQ: TRDA ): Q3 GAAP EPS of -$0.80 misses by $0.05 . Cash and cash equivalents of $53.31M For further details see: Entrada Therapeutics GAAP EPS of -$0.80 misses by $0.05

On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 for the potential treatment of patients with Duchenne muscular dystrophy who are exon 44 skipping amenable in the fourth quarter of 2022 Cash runway into 2H 2024 with...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...